Chemoimmunotherapy With Fludarabine and Rituximab Produces Extended Overall Survival and Progression-Free Survival in Chronic Lymphocytic Leukemia: Long-Term Follow-Up of CALGB Study 9712

PURPOSE: The addition of rituximab to fludarabine-based regimens in chronic lymphocytic leukemia (CLL) has been shown to produce high response rates with extended remissions. The long-term follow-up of these regimens with respect to progression, survival, risk of secondary leukemia, and impact of ge...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Woyach, Jennifer A., Ruppert, Amy S., Heerema, Nyla A., Peterson, Bercedis L., Gribben, John G., Morrison, Vicki A., Rai, Kanti R., Larson, Richard A., Byrd, John C.
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society of Clinical Oncology 2011
נושאים:
Original Reports
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3084002/
https://ncbi.nlm.nih.gov/pubmed/21321292
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.31.1811
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים